{"id":"W3004211670","doi":"10.1016/s1470-2045(19)30859-9","title":"Targeting MET in EGFR resistance in non-small-cell lung cancer—ready for daily practice?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca Schweiz; Takeda Pharmaceutical Company; Roche; Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Afatinib; Osimertinib; Medicine; Gefitinib; Erlotinib; Lung cancer; T790M; Cancer research; Tyrosine kinase; Oncology; Resistance mutation; Internal medicine; Cancer; Epidermal growth factor receptor; Biology; Receptor; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004619446,0.0009518498,0.002003235,0.0008637593,0.002792034,0.005332231,0.001854653,0.05422024,0.01208617],"category_scores_gemma":[0.0238436,0.0007184613,0.00153846,0.0007334603,0.003434895,0.006544031,0.002419153,0.0369896,0.008887134],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00497519,"about_ca_system_score_gemma":0.005921426,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004565862,"about_ca_topic_score_gemma":0.01195826,"domain_scores_codex":[0.9954319,0.001438626,0.0005028862,0.0003975679,0.001568434,0.0006606151],"domain_scores_gemma":[0.9873053,0.006320575,0.0008555948,0.0003090077,0.001680567,0.003528903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009077639,0.00004201933,0.0002519653,0.0000778411,0.00001598466,0.0005245561,0.00004603843,0.00007774304,0.0001728137,0.003126825,0.9776285,0.01794495],"study_design_scores_gemma":[0.0002769303,0.0001440287,0.0006198817,0.0004751108,0.00003527418,0.0009123075,0.0002434887,0.0005881975,0.0001478515,0.01901498,0.9774793,0.00006260318],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0001252995,0.003261762,0.00007049354,0.9819691,0.0125066,0.00000658759,0.00003660953,0.00001907766,0.002004573],"genre_scores_gemma":[0.002254993,0.00297092,0.0002382188,0.9345622,0.05433921,0.00003180737,0.00003720371,0.00001947996,0.005546015],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.05422024,"threshold_uncertainty_score":0.04043221,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04625051728837148,"score_gpt":0.4013117916393306,"score_spread":0.3550612743509591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}